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Abstract
Background: Rodent kindling induced by PTZ is a widely used model of epileptogenesis and AED testing.
Overlapping pathophysiological mechanisms may underlie epileptogenesis and other neuropsychiatric
conditions. Besides epilepsy, AEDs are widely used in treating various neuropsychiatric disorders.
Mechanisms of AEDs' long term action in these disorders are poorly understood. We describe here a
Drosophila systems model of PTZ induced locomotor plasticity that is responsive to AEDs.
Results: We empirically determined a regime in which seven days of PTZ treatment and seven days of
subsequent PTZ discontinuation respectively cause a decrease and an increase in climbing speed of
Drosophila adults. Concomitant treatment with NaVP and LEV, not ETH, GBP and VGB, suppressed the
development of locomotor deficit at the end of chronic PTZ phase. Concomitant LEV also ameliorated
locomotor alteration that develops after PTZ withdrawal. Time series of microarray expression profiles
of heads of flies treated with PTZ for 12 hrs (beginning phase), two days (latent phase) and seven days
(behaviorally expressive phase) showed only down-, not up-, regulation of genes; expression of 23, 2439
and 265 genes were downregulated, in that order. GO biological process enrichment analysis showed
downregulation of transcription, neuron morphogenesis during differentiation, synaptic transmission,
regulation of neurotransmitter levels, neurogenesis, axonogenesis, protein modification, axon guidance,
actin filament organization etc. in the latent phase and of glutamate metabolism, cell communication etc.
in the expressive phase. Proteomic interactome based analysis provided further directionality to these
events. Pathway overrepresentation analysis showed enrichment of Wnt signaling and other associated
pathways in genes downregulated by PTZ. Mining of available transcriptomic and proteomic data pertaining
to established rodent models of epilepsy and human epileptic patients showed overrepresentation of
epilepsy associated genes in our PTZ regulated set.
Conclusion:  Systems biology ultimately aims at delineating and comprehending the functioning of
complex biological systems in such details that predictive models of human diseases could be developed.
Due to immense complexity of higher organisms, systems biology approaches are however currently
focused on simpler organisms. Amenable to modeling, our model offers a unique opportunity to further
dissect epileptogenesis-like plasticity and to unravel mechanisms of long-term action of AEDs relevant in
neuropsychiatric disorders.
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Background
Epileptogenesis is poorly understood in cellular and
molecular terms [1,2]. A systems level understanding of
epileptogenesis – a network problem that may involve
molecular, structural, and functional alterations in the
brain – is expected to facilitate development of novel
antiepileptogenic, disease-modifying, and neuroprotec-
tive agents [3]. Besides epilepsy, AEDs are also used in
treating various other neurological and psychiatric condi-
tions [4-6]. Overlapping pathophysiological mechanisms
may underlie epilepsy and these other nonepileptic con-
ditions [4,7]. Kindling is a model of brain plasticity in
which recurrent activation of neural pathways results in
an increased susceptibility to evoked seizures that ulti-
mately progresses to spontaneous seizures [8]. Kindling in
rodents is widely used to model epileptogenesis [1,2] –
process whereby structural and functional changes occur
following an insult that in some cases result in epilepsy
and processes that contribute to the progression observed
in some epilepsies including post-seizure cognitive and
emotional deficits – and to test AEDs [9-13]. Not surpris-
ingly, kindling-like phenomena is also considered rele-
vant in various neuropsychiatric conditions [14-16]. Only
a limited understanding exists at present as to how the ini-
tial electrographic seizure-induced changes in synaptic
transmission and gene expression relate to permanent
alteration in brain function induced by kindling [17].
Seizure in Drosophila and man have several similarities,
and the utility of the fruit fly as a genetic model system for
studying human seizure disorders and seizure-susceptibil-
ity has clearly been demonstrated [18-23]. Drosophila sys-
tem has also been found useful in anticonvulsant drug
screening and drug target identification [24-27]. The ulti-
mate goal of systems biology is to delineate and to com-
prehend the functioning of complex biological systems in
such details that predictive models of human diseases
could be developed [28]. However, due to immense com-
plexity of higher organisms, systems biology approaches
are currently focused on developing simple organisms as
integrative models [29,30]. For example, inherent com-
plexity of mammalian brain however does not render the
available rodent epilepsy models as amenable to systems
modeling [3]. Given the above, we selected Drosophila for
developing a first ab initio systems level model of brain
plasticity that might be relevant in understanding mecha-
nisms underlying epileptogenesis and AEDs' long-term
therapeutic action in these neuropsychiatric conditions.
Rodent kindling induced by PTZ is the most popular phar-
macologically induced kindling model that provides an
acceptable approach for quantifying epileptogenesis and
for testing AEDs [31]. In rodents, PTZ kindling is induced
by repeated injection of a subconvulsant dose of the
GABA antagonist over several weeks, resulting in partially
and fully kindled animals with the latter group showing
clonic-tonic seizures; once kindled, the state of behavioral
hyperexcitability persists for up to several weeks after dis-
continuation of chemoconvulsant treatment [14,32].
Increased seizure susceptibility is known to occur via exci-
tatory GABAergic signaling in Drosophila [19]. Moreover,
chronic exposure to PTZ, a GABA antagonist, has been
reported to cause seizure phenotypes in Drosophila larvae
[21]. We thus selected PTZ for systems modeling. Altered
locomotor activity is one of the kindling and postkindling
behavior in rats and mice [33,34]. Also, seizure-like activ-
ity in Drosophila adults is known to be associated with loss
of motor coordination, and altered locomotor activities
[35]. Locomotor activity is a complex behavior and differ-
ent neural systems may influence it in fly [36]. Locomotor
behavior of Drosophila adults is used to model neuropsy-
chiatric conditions [37]. Given the above, we selected Dro-
sophila  adults and focused on developing a locomotor
behavior based model.
Methods
Fly culture and harvesting
D. melanogaster wild type Oregon-R strain was used. Rou-
tine cultures were maintained at 24 + 1°C, 60% RH, and
12 hrs light (9 AM to 9 PM) and 12 hrs dark cycle. Stand-
ard fly medium consisting of agar-agar, maize powder,
brown sugar, dried yeast and nipagin was used. Standard
methods of fly handling and manipulation were fol-
lowed. Stringency required in behavioral studies was
strictly adhered to at various levels, conditions of housing,
exposure to anesthetic agent, light intensity, for example.
Three to four days old unmated male flies were used to
begin all experiments except dsRNA microinjection. For
microinjection, 5–6 day old flies were used.
Drug dosage and treatment
LC50, defined as concentration in normal fly media caus-
ing 50% lethality in seven days, was determined for PTZ
and the AEDs (results not presented). Unless mentioned
otherwise, half of LC50, 8, 3.48, 0.33 and 5 mg/ml for PTZ,
ETH, NaVP (all from Sigma-Aldrich), and LEV (Levesam
500, Nicholas Piramal), respectively, was used. As GBP
and VGB (both from Sigma-Aldrich) did not cause
lethality up to 16 and 24 mg/ml respectively, the same
concentrations were used in all the experiments. Thirty
flies were housed in each treatment vial. Flies were main-
tained at 24 + 1°C, 60% RH, and 12 hrs light (9 AM to 9
PM) and 12 hrs dark cycle.
Locomotor assays
Climbing speed was measured using an indigenously
developed semi-manual method that was validated by
DIAS (v. 3.4.2, Soll Technologies). In semi-manual assay,
a glass column of 2 cm internal diameter and 30 cm inter-
nal length, i.e., length between the two cotton plugs, wasBMC Systems Biology 2009, 3:11 http://www.biomedcentral.com/1752-0509/3/11
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used in the assays. The column was marked with lines at
every cm along the length. Each fly was first familiarized
in the vertically placed column for 90 seconds. The fly was
thereafter brought to the bottom of the tube, by tapping
the tube on a piece of packing foam. As soon as the fly had
fallen on the cotton plug at the bottom, the tube was as
such placed vertically and, in semi-manual method, a
"dot/comma" recording, explained below, was applied
the moment fly crossed a height of 5 cm. In "dot/comma"
recording, the locomotor activity of a single fly was mon-
itored by keeping pressed the dot key or the comma key of
a personal computer, to record a moving or resting fly
respectively. Dots and commas were subsequently trans-
formed in activity and rest period respectively, using the
cursor speed. Climbing speed was calculated using the fol-
lowing formula, s = h/t, where s = climbing speed, h =
height climbed in cm, and t = activity period in sec. One
fly each from different treatment groups was first scored as
described below, discarded, and the exercise repeated.
Measurements were taken at room temperature, between
9 AM to 9 PM. Climbing was considered complete when
the fly reached the cotton plug at the top, fell to the bot-
tom after climbing a certain height beyond 5 cm mark, or
stopped after climbing to a certain height for more than
10 sec. Comma was applied only when the fly took rest.
The vertical locomotor assay was adapted to measure hor-
izontal (spontaneous) locomotor activities. A single fly
was first brought to the middle of the column by gentle
shaking and then the fly movement was constantly mon-
itored for 90 sec by keeping pressed the dot key or the
comma key of a personal computer, to record a moving or
resting fly respectively. The total number of lines that a fly
crossed in the 90 sec assay time was counted and noted
down at the end of the dot/comma recording. The data
was normalized for 90 sec and the dots and commas were
subsequently transformed in rest and activity period
respectively, using the cursor speed. Walking speed was
obtained by dividing the lines (cm) a fly crossed (distance
walked, d) by time, in sec, it spent in activity (activity
period, a), during the 90 sec assay period. For some flies,
both "d" and "a" were found to be zero. Such individuals
were excluded while calculating population mean of s.
Finally, the horizontal assay was used to extract four loco-
motor parameters, namely, activity period, distance
walked and walking speed. The semi-manual climbing
assay described above was validated using DIAS. TD was
measured using DIAS, by video recording flies in the treat-
ment vials with media containing 16 mg/ml PTZ. TD is
the net path length divided by the total path length. This
gives 1.0 for a completely straight path and a smaller value
for a meandering path.
Microarray expression profiling
Total cellular RNA was isolated from fly heads belonging
to five biological replicates, four for microarray profiling,
and one for real-time PCR. Each replicate represented four
independent sets of control and treated flies. Each inde-
pendent set consisted of eight vials, four each of NF and
PTZ, treated in parallel. Similar design was followed for
control NF-NF control microarray experiment. Thirty flies
were treated in each vial. Heads of 120 flies were pooled
for isolating each RNA sample. Flies were frozen in 50 ml
falcon tubes in liquid nitrogen. Two cooled sieves were
arranged such that the larger sieve (mesh size 850 mm)
was placed on top of the smaller one (mesh size 355 mm).
Frozen flies were shaken 4–5 times in the falcon and
poured onto the top sieve. The flies were brushed gently
with a paint brush till all heads were sieved out on the bot-
tom sieve. Bodies that remained on the top sieve were dis-
carded and heads were collected in cryovials and kept
frozen at -80°C. Total RNA was isolated from frozen fly
heads using TRI REAGENT (Sigma), according to the man-
ufacturer's protocol. RNA was quantified using spectro-
photometer. RNA quality was checked by running 1%
agarose gel.
Microarray -cDNA Synthesis Kit, -Target Purification Kit,
and -RNA Target Synthesis Kit (Roche) were used to gen-
erate labeled antisense RNA. Starting with 10 μg of total
cellular RNA, Eberwine method (kits from Roche) was
used to generate cDNA and thereafter Cy3 and Cy5 (Amer-
sham) labeled antisense RNA. The Cy3 and Cy5 labeled
aRNAs (control and treated) were pooled together and
precipitated, washed, air-dried, and dissolved in 18 MΩ
RNAase free water (Sigma). The recovery of labeled aRNAs
was checked using spectrophotometer and agarose gel
electrophoresis. A total of 16 microarrays (12Kv1, CDMC)
were hybridized, four each for NF-NF control (0 hr); NF-
PTZ, 12 hrs; NF-PTZ, 2nd day; NF-PTZ, 7th day. Out of four,
two slides were dye-swaps. Hybridization solution was
prepared by mixing hybridization buffer (DIG Easy Hyb,
Roche), 10 mg/ml salmon testis DNA (0.05 mg/ml final
concentration, Sigma) and 10 mg/ml yeast tRNA (0.05
mg/ml final concentration, Sigma) and added to the
labeled product. This mixture was denatured at 65°C and
applied onto cDNA microarray slides. The slides were cov-
ered by lowering down a 24 × 60 mm coverslip (ESCO,
Portsmouth, USA). Hybridization was allowed to take
place in hybridization chamber (Corning) at 37°C for 16
hrs. After hybridization, coverslips were removed by sub-
merging the slides in a solution containing 1× SSC and
0.1% SDS at 50°C. Slides were washed (three times for 15
minutes each) in a coplin jar at 50°C with occasional
swirling and then transferred to 1× SSC and washed with
gentle swirling at room temperature (twice for 15 minutes
each). Finally, slides were washed in 0.1× SSC for 15 min-
utes and then liquid was quickly removed from the slide
surface by spinning at 600 rpm for 5 minutes. Slides were
scanned at 10 μm resolution using GenePix 4000A Micro-
array Scanner (Molecular Devices), and the images pre-BMC Systems Biology 2009, 3:11 http://www.biomedcentral.com/1752-0509/3/11
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processed and quantified using Gene Pix Pro 6.0
(Molecular Devices).
Statistics
Unless mentioned otherwise, pair-wise Student's t-test,
two-tailed, heteroscedastic, uncorrected, was performed
for behavioral analysis. In microarray gene expression
analysis, ratio based data normalization and selection of
features were performed using Acuity 4.0 (Molecular
Devices). All Spots with raw intensity less then 100 U and
less then twice the average background was ignored dur-
ing normalization. Normalized data was filtered for the
selection of features before further analysis. Only those
spot were selected which contained only a small percent-
age (< 3) of saturated pixels, were not flagged bad or
found absent (flags > 0), had relatively uniform intensity
and uniform background [Rgn R2 (635/532) > 0.6] and
were detectable above background (SNR > 3). Analyzable
spots in at least three of four biological replicates per-
formed were retrieved for downstream analysis using SAM
3.0 (Excel Add-In) [38], under the conditions of one class
response and 100 permutations. Wherever available, non-
CG number genes were converted to CG numbers mainly
using BDGP http://www.flybase.org. Gene IDs were con-
verted to FBgn numbers using GeneMerge http://gene
merge.bioteam.net/convertgenenames.html, before
GOTool Box [39] was used to retrieve overrepresented
biological processes in up- or down- regulated genes,
under the settings, ontology, biological process; mode, all
terms; reference, genome; evidence, all-all evidence; spe-
cies, D. melanogaster; GO-stats; statistic test, hypergeomet-
ric http://burgundy.cmmt.ubc.ca/GOToolBox/. DAVID
[40] was used for pathway enrichment analysis http://
david.abcc.ncifcrf.gov/home.jsp. P values were obtained
with or without correction for multiple hypotheses test-
ing, as indicated in the results section. Hypergeometric
distribution probabilities for genes and GO processes
were calculated assuming population sizes of 10000,
approximately the number of unique genes in the arrays,
and 4041, a previously estimated number for Drosophila
[41], respectively.
Results and Discussion
Chronic PTZ locomotor model and its validation by AEDs
We first explored, through empirical testing, if PTZ could
produce proconvulsant-like effect in Drosophila  adults.
Though convulsions were not observed, visual examina-
tion indicated that flies treated with 16 mg/ml of PTZ for
12 hrs exhibit hyperkinetic behavior. Software-based
analysis of video recordings showed a decreased 'total
directionality' in PTZ treated flies compared to control,
i.e., flies treated with normal food (NF). Mean + S.E of
'total directionality' was found to be 0.39 + 0.07 (n = 11)
and 0.19 + 0.05 (n = 11) for flies fed with NF and with
food containing PTZ, respectively. A significant (p = 0.04)
difference in 'total directionality' demonstrated that 16
mg/ml PTZ causes flies to take a more circuitous path. As
16 mg/ml was the LC50  dose (lethality data not pre-
sented), we used half of this dose, i.e., 8 mg/ml, as a sub-
hyperkinetic dose for further developing and evaluating a
chronic model. Though seizure-like behavior was never
observed in flies treated with 8 mg/ml in a chronic man-
ner, we empirically determined a regime in which seven
days of chronic PTZ treatment and seven following days of
PTZ discontinuation respectively caused a decrease and an
increase in startle-induced climbing speed in flies (Figure
1; for DIAS validation of climbing assay, see additional
file 1). Examining the effect of PTZ on various horizontal
locomotor activities and non-locomotor parameters,
namely, courtship duration, fertility, and body weight
showed that chronic treatment induced decrease and sub-
sequent withdrawal induced increase in climbing speed
are specific (for detailed results, see additional file 2).
We next examined if AEDs are effective in ameliorating
climbing alterations induced by chronic PTZ and with-
drawal from chronic PTZ. Concomitant treatment with
PTZ and ETH, GBP, VGB, NaVP or LEV for seven days
showed the last two AEDs as effective in alleviating PTZ
induced climbing speed deficit in flies on 7th day (Figure
2A). NaVP and LEV were thus found to be effective in the
fly model. To examine long term effectiveness of AEDs, we
concomitantly treated flies with PTZ and an AED for seven
days and measured climbing speed seven days after with-
drawal of the two drugs. Only LEV, not other AEDs, was
found to ameliorate climbing speed increase caused by
withdrawal from chronic PTZ (Figure 2B). LEV thus
exerted a long term effect. To examine the possibility that
the above validation results might have been confounded
by AEDs own locomotor effects, we treated flies with
AEDs for seven days and measured climbing speed at the
end of this chronic treatment as well as seven days after
AEDs were withdrawn. ETH, VGB and LEV, not NaVP and
GBP, were found to decrease climbing speed at the end of
chronic treatment (Figure 3A). Independent speed lower-
ing effect of NaVP and LEV (Figure 3A) could not be con-
sidered to confound the observation that these AEDs
ameliorate decrease in climbing speed caused by PTZ (Fig-
ure 2A). After withdrawal, none of the AEDs were found
to cause climbing abnormality (Figure 3B). Cumulatively,
the above results validated the PTZ model as predictive of
AEDs.
NaVP and LEV, not ETH, GBP and VGB, were found to be
effective in our chronic PTZ model of locomotor plastic-
ity. NaVP and LEV are known to suppress both kindling
development as well as kindled seizure in rodent models
[42,43]. Clinical trials however suggest that LEV, not
NaVP, possesses antiepileptogenic activity [9,44,45].
Overall, the profiles of NaVP and LEV in the fly modelBMC Systems Biology 2009, 3:11 http://www.biomedcentral.com/1752-0509/3/11
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were consistent with their therapeutic potential. Ineffec-
tiveness of other AEDs in the fly model however suggested
that our model is only partly predictive of therapeutic
potential. Clinical relevance of the model is also limited
by the fact that the drug doses used in developing the
model were selected either empirically or based on toxic-
ity.
Time series of transcriptomic changes underlying chronic 
PTZ
We generated expression profiles of fly heads at four time
points – 0 hr; 12 hrs of PTZ, the beginning phase; 2nd day
of PTZ, the latent phase; and 7th day of PTZ, the behavio-
rally expressive phase (Figure 4). The full microarray data
set has been deposited in the Gene Expression Omnibus
http://www.ncbi.nlm.nih.gov/geo/ under accession series
GSE7037, GSE7120 and GSE7200. Total number of ana-
lyzable genes in SAM showed uniformity across time
points – 4369, 4637, 5259 and 4297, in that order. At 0
hr, no gene was detected as differentially expressed below
96% FDR. At 12 hrs, 2nd day and 7th day time-points, 23,
2439 and 265 genes were found to be downregulated at
22.76%, 13.74% and 23.03% FDR, in that order (for gene
lists, see additional file 3). No upregulated gene was
detected at above FDRs. Given small number of genes at
12 hrs, we considered these FDRs as the best compromise
between uniformity across time points and acceptability
in terms of incorporating false positives. We therefore
used the above gene lists for all subsequent analysis.
Detection of genes which are known to express at a rela-
tively low level in fly brain, diss  (CG4211),  dnc
(CG32498), dco (CG2048), per (CG2647), for example
[46], as differentially expressed genes in PTZ time series
demonstrated that our expression profiling was efficient.
Figure 1
Chronic PTZ and subsequent withdrawal induced climbing  abnormalities Figure 1
Chronic PTZ and subsequent withdrawal induced 
climbing abnormalities. Mean + S. E. (n = 24) of climbing 
speed in flies used for control experiments and for simulating 
PTZ induced kindling-like plasticity. In control experiments, 
five batches of flies were treated with NF for either 7 days 
(A) or 14 days (B) before measuring climbing speed. In 
chronic PTZ experiment (C), climbing speed was measured 
on 12 hrs, 2nd day and 7th day of PTZ treatment and then on 
3rd day, 5th day, and 7th day after PTZ withdrawal. For control 
climbing assay to examine consistency among NF flies housed 
in different vials (A and B), one-way ANOVA as well as pair-
wise Student's t-test, two-tailed, heteroscedastic, uncor-
rected, was performed. After finding no significant variation 
by either method, Student's t-test was performed as above 
for chronic PTZ experiment (C). * indicates significant differ-
ence between control (NF) and PTZ treatment. p values 
(pair-wise Student's t-test, two-tailed) are provided over 
asterisks. For details, see text.BMC Systems Biology 2009, 3:11 http://www.biomedcentral.com/1752-0509/3/11
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Effect of AEDs on chronic PTZ and subsequent withdrawal induced climbing speed alterations Figure 2
Effect of AEDs on chronic PTZ and subsequent withdrawal induced climbing speed alterations. Mean + S. E. (n = 
24) of climbing speed in flies after (A) seven days of combination treatment (B) seven days of withdrawal. The difference 
between PTZ and PTZ+NaVP in A and between PTZ and PTZ+LEV in B is significant. The difference between PTZ and 
PTZ+LEV, and between PTZ+NaVP and PTZ+LEV is insignificant in A. Notably, comparison of PTZ+LEV in A with pooled NF 
samples in Figure 1A and 1C (7d) showed significant (p = 0.0005) difference in climbing speed.BMC Systems Biology 2009, 3:11 http://www.biomedcentral.com/1752-0509/3/11
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Further, a few genes which were used to validate microar-
ray results by real time PCR corroborated the transcrip-
tomic profiles (for details, see additional file 4). Notably,
significant overlap of genes between adjacent time points
[hypergeometric distribution; p = 5.3 × 10-6 between 12
hrs and 2nd day, p = 1.9 × 10-22 between 2nd and 7th day]
demonstrated that our expression profiling was efficient
enough to capture the spectrum of transcriptomic altera-
tions underlying chronic PTZ phase.
We first examined if 'seizure' genes already described in
Drosophila show enrichment in our PTZ induced downreg-
ulated genes. Evidence suggests conserved mechanisms
between  Drosophila  bang-sensitive mutants and human
seizure disorders [20]. Molecular defects in five such
mutants involve genes encoding mitochondrial ribos-
omal protein (CG7925), ADP/ATP translocase
(CG16944), the citrate synthase (CG3861), an eth-
anolamine kinase (CG3525), and an aminopeptidase
(CG5518). Prevalence of mitochondrial function disrupt-
ing defects in bang-sensitive mutants suggests that
impaired energy metabolism may underlie the affected
behavior [20]. Importantly, human seizure disorders have
been linked to mutations in genes encoding pyruvate car-
boxylase, and pyruvate dehydrogenase, the two enzymes
upstream of citrate synthase, as well as to mutations
affecting various steps in the TCA cycle [20]. Our microar-
rays had all the above bang-sensitive genes spotted except
CG7925. Notably, all four spotted seizure genes were
downregulated by PTZ. This overlap was statistically sig-
nificant (hypergeometric distribution, p = 0.004).
We next examined enrichment of biological processes in
PTZ time series genes. After Bonferroni correction for mul-
tiple statistical testing, no GO biological process was
observed as overrepresented at 12 hrs. Several processes
were however found to be enriched in 2nd and 7th day gene
sets. Consistent with unusually large number of genes
affected in the latent phase, the 2nd day genes overrepre-
sented a diversity of processes including neuron morpho-
genesis during differentiation, synaptic transmission,
regulation of neurotransmitter levels, neurogenesis,
axonogenesis, protein modification, regulation of tran-
scription, axon guidance, actin filament organization etc.
(Table 1). In contrast, the behaviorally expressive phase,
i.e., 7th day, overrepresented a smaller number of GO
processes which included phototransduction, glutamate
metabolism, cell communication etc (Table 2). Since
entire fly heads including eyes were used for expression
profiling, enrichment of phototransduction related proc-
esses most likely reflected PTZ's effect on visual percep-
tion. In brief, chronic PTZ was found to be associated with
downregulation of a large number of genes which were
enriched in a diversity of biological processes.
For providing direction to the transcriptomic changes, we
first overlaid all 2574 genes present in 12 hrs, 2nd day and
7th day sets onto protein interactome map of D.  mela-
nogaster  (interaction database BioGRID v 2.0, http://
www.thebiogrid.org/index.php visualization software
platform Osprey v. 1.2.0, http://biodata.mshri.on.ca/
osprey/servlet/Index) which consisted of 7358 genes (ver-
tices) and 24984 connections (edges) [47]. Out of 2574
PTZ regulated genes, 1633 were present in the fly interac-
tome. We retrieved PTZ gene specific subinteractome that
consisted of 1633 vertices and 1485 edges. In this subin-
teractome map, 632 genes were found to be loner, i.e.,
they did not show any within group interaction. We here-
Effect of chronic AEDs and their subsequent withdrawal on  climbing speed Figure 3
Effect of chronic AEDs and their subsequent with-
drawal on climbing speed. Mean + S. E. (n = 24) of climb-
ing speed in flies after (A) seven days of treatment and (B) 
seven days of subsequent withdrawal. For details, see text.BMC Systems Biology 2009, 3:11 http://www.biomedcentral.com/1752-0509/3/11
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Time-series of Drosophila head microarray gene expression profiles Figure 4
Time-series of Drosophila head microarray gene expression profiles. Hierarchical clustering of 0 hr, 12 hrs, 2nd day 
and 7th day expression profiles. City Block similarity metric and average linkage methods were used for clustering of arrays. 
Each time point represents mean of normalized log2 ratio (635/534) of four biological replicates with balanced dye-swaps. The 
cluster was generated using Acuity 4.0.BMC Systems Biology 2009, 3:11 http://www.biomedcentral.com/1752-0509/3/11
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after focused on within group interaction network which
was comprised of 1001 genes and 1485 interactions (for
interacting genes, see additional file 5). We next exam-
ined which of the 12 hrs gene(s) shows statistically signif-
icant overinteraction in the network of 1001 vertices and
1485 edges. Among 13 beginning phase, i.e., 12 hrs, genes
present in the network, only the C-terminal Binding Pro-
tein (CtBP, CG7583) was found to overinteract (hyperge-
ometric distribution after Bonferroni correction, p  =
0.004; Table 3; Figure 5). CG7583 and its direct interact-
ing partners, a network comprising of 17 genes, showed
overrepresentation of various GO processes which were
Table 1: Overrepresented GO biological processes in genes downregulated on 2nd day of PTZ treatment
GO_ID TERM P_VALUE
GO:0000902 cell morphogenesis 1.09E-16
GO:0030154 cell differentiation 1.41E-11
GO:0051179 localization 3.35E-11
GO:0007154 cell communication 7.58E-09
GO:0019226 transmission of nerve impulse 9.01E-09
GO:0006810 transport 1.15E-08
GO:0007267 cell-cell signaling 1.18E-08
GO:0007268 synaptic transmission 1.74E-08
GO:0007399 nervous system development 2.30E-07
GO:0019219 regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolic process 2.55E-06
GO:0001505 regulation of neurotransmitter levels 3.93E-06
GO:0022008 neurogenesis 5.55E-06
GO:0048666 neuron development 1.70E-05
GO:0030030 cell projection organization and biogenesis 2.57E-05
GO:0048699 generation of neurons 5.83E-05
GO:0031175 neurite development 6.86E-05
GO:0030182 neuron differentiation 0.0001055
GO:0007269 neurotransmitter secretion 0.0003908
GO:0007010 cytoskeleton organization and biogenesis 0.0006173
GO:0016070 RNA metabolic process 0.0006893
GO:0008104 protein localization 0.0008227
GO:0007626 locomotory behavior 0.0009849
GO:0007409 axonogenesis 0.0011489
GO:0006464 protein modification process 0.0027655
GO:0007155 cell adhesion 0.0030866
GO:0045449 regulation of transcription 0.0043652
GO:0043687 post-translational protein modification 0.005309
GO:0048489 synaptic vesicle transport 0.0067834
GO:0016477 cell migration 0.0075502
GO:0006928 cell motility 0.0102359
GO:0007411 axon guidance 0.0141982
GO:0007517 muscle development 0.0142275
GO:0046530 photoreceptor cell differentiation 0.0197214
GO:0001754 eye photoreceptor cell differentiation 0.0297998
GO:0048512 circadian behavior 0.0376882
GO:0008361 regulation of cell size 0.0383864
Some non-specific processes are not shown. For details, see text. p values are after Bonferroni correction.
Table 2: Enriched GO biological processes in genes downregulated on 7th day of PTZ treatment
GO_ID TERM P_VALUE
GO:0019752 carboxylic acid metabolic process 0.0004902
GO:0007602 phototransduction 0.0023181
GO:0009064 glutamine family amino acid metabolic process 0.0034414
GO:0006536 glutamate metabolic process 0.0052215
GO:0007154 cell communication 0.0083634
GO:0006538 glutamate catabolic process 0.0117205
Some non-specific processes are not shown. For details, see text. p values are after Bonferroni correction.BMC Systems Biology 2009, 3:11 http://www.biomedcentral.com/1752-0509/3/11
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mainly related to transcriptional regulation and cell fate
determination (Table 4). Transcriptional alteration was
thus identified as the most proximal effect of PTZ. To
complete adding direction, we retrieved enriched proc-
esses in genes which showed interaction with interacting
partners of CG7583 in the self-interacting network of our
PTZ genes, and so on, till completion; of 1001 genes, 898
were consumed by this CG7583 centered network.
Enrichment of cell morphogenesis and protein import
into nucleus; neuron differentiation, neurogenesis,
axonogenesis, axon guidance, small GTPase mediated sig-
nal transduction, actin filament organization, cell growth,
transmembrane receptor protein tyrosine kinase signaling
pathway, eye photoreceptor cell differentiation, regula-
tion of cell shape and regulation of cell size; phospholi-
pase C activation and positive regulation of hydrolase
activity was observed, in that order (for complete lists of
enriched GO processes, see additional file 6). Broadly,
process enrichment analysis guided by protein interac-
tome suggested that chronic PTZ sequentially downregu-
lates transcription, neurogenesis/axonogenesis/axon
guidance and phospholipase C activation. This was con-
sistent with original time series analysis presented above
(Tables 1 and 2), except that glutamate metabolism
related processes enriched on 7th day (Table 2) were not
recovered by interactome guided analysis. Seventh day
genes under these categories – CG7145, CG5320 (Gdh),
CG14994 (Gad1), CG1743 (Gs2) and CG8430 (Got1) –
are poorly connected in the entire fly interactome (range,
0–3 interactions). It is likely that non-recovery of gluta-
mate metabolism related processes reflect poor interac-
tion of the genes involved. Cumulatively, the above
results suggested that sequential downregulation of gene
expression, neurogenesis/axonogenesis/axon guidance,
phospholipase C activation and glutamate metabolism
characterize our fly behavioral model.
We next examined enrichment of biochemical and signal-
ing pathways in all 338 genes which were part of enriched
biological processes in CG7583 centered network, listed
in additional file 6. Although no pathway was found to be
enriched after Bonferroni correction for multiple hypoth-
eses testing, our gene set overrepresented various path-
ways based on unadjusted p  values (Table 5). Since
enrichment of these pathways is consistent with process
enrichment analysis presented above – TGF-beta signaling
pathway and Wnt signaling pathway are consistent with
Overinteraction of CG7583 (CtBP) Figure 5
Overinteraction of CG7583 (CtBP). Interacting partners 
of CG7583 in the network of self-interacting PTZ regulated 
genes are shown. For details, see text.
Table 3: Interacting partners of 12 hrs genes
GENES SUBNETWORK INTERACTION NETWORK INTERACTION P_VALUE
CG11958 1 1 1.768551
CG4799 9 32 0.195
CG8428 1 4 4.55
CG3241 1 3 3.9
CG9238 7 22 2.08
CG11064 1 4 4.55
CG11325 1 2 2.99
CG11963 2 11 3.51
CG9448 1 5 4.94
CG11094 8 46 1.56
CG7583 16 49 0.00455
CG1600 3 4 0.104
CG10078 2 6 1.95
Numbers of partners in the subnetwork of PTZ regulated genes and in the entire interactome network are shown. For details, see text. p values 
are after Bonferroni correction. Note overinteraction of CG7583 (CtBP) in the subnetwork.BMC Systems Biology 2009, 3:11 http://www.biomedcentral.com/1752-0509/3/11
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Table 4: Overrepresented GO biological processes among CG7583 (CtBP) and its direct interacting partners
GO_ID TERM P_VALUE
GO:0000122 negative regulation of transcription from RNA polymerase II promoter 8.98E-08
GO:0045934 negative regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolic process 1.53E-07
GO:0006357 regulation of transcription from RNA polymerase II promoter 1.30E-06
GO:0045892 negative regulation of transcription, DNA-dependent 2.50E-06
GO:0006366 transcription from RNA polymerase II promoter 1.72E-05
GO:0019219 regulation of nucleobase, nucleoside, nucleotide and nucleic acid metabolic process 5.69E-05
GO:0045449 regulation of transcription 0.0003655
GO:0045165 cell fate commitment 0.0004668
GO:0016070 RNA metabolic process 0.0005037
GO:0032774 RNA biosynthetic process 0.0033751
GO:0006139 nucleobase, nucleoside, nucleotide and nucleic acid metabolic process 0.0037604
Partners are limited to the subnetwork of PTZ regulated genes. Some non-specific processes are not shown. For details, see text. p values are after 
Bonferroni correction.
Enrichment of Wnt signaling pathway Figure 6
Enrichment of Wnt signaling pathway. Pink boxes indicate CG7583 extended network genes that overrepresent one or 
more GO processes. For details, see text.BMC Systems Biology 2009, 3:11 http://www.biomedcentral.com/1752-0509/3/11
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neurogenesis/axonogenesis/axon guidance, for example –
we considered the enriched pathways as significant. Genes
showing downregulation in PTZ fly model are indicated
in the enriched pathways shown in Figures 6, 7, 8, 9, 10,
11. Remarkably, Wnt signaling which is the most signifi-
cant pathway in our analysis has previously been impli-
cated in epilepsy [48]. As depicted in Figures 6, Wnt
signaling is directly connected to TGF-beta (Figure 7) and
MAPK signaling (Figure 8) pathways. Further, one or
more of these pathways are also linked to JAK-STAT (Fig-
ure 9) and Cell Communication (Figure 10) pathways.
Therefore, except Dorso-Ventral Axis Formation (Figure
11) which does not show any direct or indirect connec-
tion with Wnt signaling, all other five pathways enriched
in our gene set are marked by biological plausibility in
epileptogenesis.
We further examined the relevance of fly model in epi-
lepsy and related neurological and psychiatric conditions
through mining reported transcriptomic and proteomic
data related to available animal models and human
patients. For this, we retrieved rat, mouse and human
homologs (FLIGHT, homologene; http://
www.flight.licr.org/) of above mentioned 1001 genes
which were downregulated by PTZ and were part of self-
interacting network (for homolog gene lists, see addi-
tional file 7). The homologs were then examined to find
out if they overrepresent genes/proteins reportedly down-
regulated in transcriptomic and proteomic studies on
rodent models or human epilepsy (for gene/protein lists,
see additional file 8). Comparison with individual studies
did not reveal statistically significant overlap. Since over-
lap was also not observed even among reported studies,
we pooled down- and up-regulated genes therein sepa-
rately and matched with our fly gene list. Notably, down-
regulated genes in fly showed significant match with
reported downregulated (p = 0.017) but not upregulated
(p = 0.082) genes. This direction specific overlap demon-
strated that our fly model is relevant in understanding epi-
leptogenesis.
Enrichment of TGF-beta signaling pathway Figure 7
Enrichment of TGF-beta signaling pathway. Pink boxes indicate CG7583 extended network genes that overrepresent 
one or more GO processes. For details, see text.BMC Systems Biology 2009, 3:11 http://www.biomedcentral.com/1752-0509/3/11
Page 13 of 17
(page number not for citation purposes)
Enrichment of MAPK signaling pathway Figure 8
Enrichment of MAPK signaling pathway. Pink boxes indicate CG7583 extended network genes that overrepresent one 
or more GO processes. For details, see text.
Enrichment of Jak-STAT signaling pathway Figure 9
Enrichment of Jak-STAT signaling pathway. Pink boxes indicate CG7583 extended network genes that overrepresent 
one or more GO processes. For details, see text.BMC Systems Biology 2009, 3:11 http://www.biomedcentral.com/1752-0509/3/11
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Conclusion
The ultimate goal of systems biology is to delineate and to
comprehend the functioning of complex biological sys-
tems in such details that predictive models of human dis-
eases could be developed [28]. However, due to immense
complexity of higher organisms, systems biology
approaches are currently focused on simpler organisms
[29,30]. We have described here a behavioral and func-
tional genomic model of chemoconvulsant-induced brain
plasticity in Drosophila. Although two among five AEDs
tested are effective in ameliorating locomotor alteration
induced by convulsant drug, flies in our model do not
exhibit seizure-like behavior. However, gene expression
alterations induced by the convulsant drug show some
similarity with expression alterations reported in estab-
lished rodent models and epileptic patients. Together,
these findings suggest that the brain plasticity involved in
the fly model may be potentially relevant in understand-
ing mechanisms underlying epileptogenesis to some
extent. Chiefly, our model shows downregulation of gene
expression and inhibition of neurogenesis/axonogenesis/
axon guidance as system level perturbations underlying
epileptogenesis-like plasticity. In terms of biochemical
pathways, our analysis supports a role of Wnt signaling
Enrichment of Cell communication pathway Figure 10
Enrichment of Cell communication pathway. Pink boxes indicate CG7583 extended network genes that overrepresent 
one or more GO processes. For details, see text.BMC Systems Biology 2009, 3:11 http://www.biomedcentral.com/1752-0509/3/11
Page 15 of 17
(page number not for citation purposes)
and other associated pathways in the pathogenesis.
Besides epilepsy, AEDs are widely used in treating various
neuropsychiatric disorders. Mechanisms of AEDs' long-
term action in these disorders are poorly understood.
Overlapping pathophysiological mechanisms may under-
lie epileptogenesis and other neuropsychiatric conditions.
Rodent kindling induced by PTZ is a widely used model
of epileptogenesis and AED testing. As our fly PTZ model
is validated by AEDs, it most importantly offers a unique
opportunity for deciphering the mechanisms of long-term
action of AEDs that is relevant in various neuropsychiatric
conditions. Due to amenability for systems level mode-
ling, candidate gene silencing, small molecule interven-
tions and dietary modifications, for example, can be
readily used in our model for generating and testing
hypotheses. In brief, the Drosophila  systems model is
expected to be valuable in identifying disease, drug target,
biomarker and pharmacogenomic candidates, and in
screening of potential therapeutic agents.
Abbreviations
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Enrichment of Dorso-ventral axis formation pathway Figure 11
Enrichment of Dorso-ventral axis formation pathway. Pink boxes indicate CG7583 extended network genes that over-
represent one or more GO processes. For details, see text.BMC Systems Biology 2009, 3:11 http://www.biomedcentral.com/1752-0509/3/11
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